Oncobiology and treatment of breast cancer in young women.
Early breast cancer
Pathobiology
Polygenic
Prognosis
Therapeutics
Transcriptomics
Young women
Journal
Cancer metastasis reviews
ISSN: 1573-7233
Titre abrégé: Cancer Metastasis Rev
Pays: Netherlands
ID NLM: 8605731
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
24
02
2022
accepted:
14
04
2022
pubmed:
1
5
2022
medline:
16
9
2022
entrez:
30
4
2022
Statut:
ppublish
Résumé
Female breast cancer emerged as the leading cancer type in terms of incidence globally in 2020. Although mortality due to breast cancer has improved during the past three decades in many countries, this trend has reversed in women less than 40 years since the past decade. From the biological standpoint, there is consensus among experts regarding the clinically relevant definition of breast cancer in young women (BCYW), with an age cut-off of 40 years. The idea that breast cancer is an aging disease has apparently broken in the case of BCYW due to the young onset and an overall poor outcome of BCYW patients. In general, younger patients exhibit a worse prognosis than older pre- and postmenopausal patients due to the aggressive nature of cancer subtypes, a high percentage of cases with advanced stages at diagnosis, and a high risk of relapse and death in younger patients. Because of clinically and biologically unique features of BCYW, it is suspected to represent a distinct biologic entity. It is unclear why BCYW is more aggressive and has an inferior prognosis with factors that contribute to increased incidence. However, unique developmental features, adiposity and immune components of the mammary gland, hormonal interplay and crosstalk with growth factors, and a host of intrinsic and extrinsic risk factors and cellular regulatory interactions are considered to be the major contributing factors. In the present article, we discuss the status of BCYW oncobiology, therapeutic interventions and considerations, current limitations in fully understanding the basis and underlying cause(s) of BCYW, understudied areas of BCYW research, and postulated advances in the coming years for the field.
Identifiants
pubmed: 35488982
doi: 10.1007/s10555-022-10034-6
pii: 10.1007/s10555-022-10034-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
749-770Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA, 71(3), 209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Paluch-Shimon, S., Cardoso, F., Partridge, A. H., Abulkhair, O., Azim, H. A., Jr., Bianchi-Micheli, G., et al. (2020). ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Annals of Oncology, 31(6), 674–696. https://doi.org/10.1016/j.annonc.2020.03.284
doi: 10.1016/j.annonc.2020.03.284
pubmed: 32199930
Narod, S. A. (2012). Breast cancer in young women. Nature Review Clinical Oncology, 9(8), 460–470. https://doi.org/10.1038/nrclinonc.2012.102
doi: 10.1038/nrclinonc.2012.102
Daly, A. A., Rolph, R., Cutress, R. I., & Copson, E. R. (2021). A review of modifiable risk factors in young women for the prevention of breast cancer. Breast Cancer, 13, 241–257. https://doi.org/10.2147/BCTT.S268401
doi: 10.2147/BCTT.S268401
pubmed: 33883932
pmcid: 8053601
Hendrick, R. E., Helvie, M. A., & Monticciolo, D. L. (2021). Breast cancer mortality rates have stopped declining in US women younger than 40 Years. Radiology, 299(1), 143–149.
doi: 10.1148/radiol.2021203476
Ghosh, J., Gupta, S., Desai, S., Shet, T., Radhakrishnan, S., Suryavanshi, P., … Badwe, R. A. (2011). Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian Journal of Cancer, 48(4), 391–396 https://doi.org/10.4103/0019-509X.92245
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., et al. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 30(8), 1194–1220. https://doi.org/10.1093/annonc/mdz173
doi: 10.1093/annonc/mdz173
pubmed: 31161190
Bajpai, J., Ventrapati, P., Joshi, S., Wadasadawala, T., Rath, S., Pathak, R., et al. (2021). Unique challenges and outcomes of young women with breast cancers from a tertiary care cancer centre in India. Breast (Edinburgh, Scotland), 60, 177–184. https://doi.org/10.1016/j.breast.2021.09.008
doi: 10.1016/j.breast.2021.09.008
Siegel, R. L., Miller, K. D., & Jemal, A. (2017). Cancer Statistics, 2017. CA, 67(1), 7–30.
pubmed: 28055103
Breast cancer incidence (invasive) statistics | Cancer Research UK. (n.d.). Retrieved February 11, 2022, from https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-invasive#heading-One
Okazaki, M., Bando, H., Tohno, E., Kujiraoka, Y., Iguchi-Manaka, A., Ichioka, E., … Hara, H. (2021). Investigation of the significance of population-based breast cancer screening among women aged under 40 years. Breast Cancer, 28(1), 75–81 https://doi.org/10.1007/s12282-020-01131-x
Nakata, K., Hiyama, E., Katanoda, K., Matsuda, T., Tada, Y., Inoue, M., et al. (2022). Cancer in adolescents and young adults in Japan: Epidemiology and cancer strategy. International Journal of Clinical Oncology, 27(1), 7–15. https://doi.org/10.1007/s10147-021-02064-x
doi: 10.1007/s10147-021-02064-x
pubmed: 34779960
Hayashi, N., Kumamaru, H., Isozumi, U., Aogi, K., Asaga, S., Iijima, K., et al. (2020). Annual report of the Japanese Breast Cancer Registry for 2017. Breast Cancer (Tokyo, Japan), 27(5), 803–809. https://doi.org/10.1007/S12282-020-01139-3
doi: 10.1007/S12282-020-01139-3
Alvarez-Bañuelos, M. T., Segura-Jaramillo, K. A., Gómez-Rivera, E. D. C., Alarcón-Rojas, C. A., Morales-Romero, J., Sampieri, C. L., et al. (2021). Age under 30 years as a predictor of poor survival in a cohort of mexican women with breast cancer. Cancer Control, 28, 10732748211047408. https://doi.org/10.1177/10732748211047408
doi: 10.1177/10732748211047408
pubmed: 34670417
pmcid: 8546434
Ntirenganya, F., Twagirumukiza, J. D., Bucyibaruta, G., Rugwizangoga, B., & Rulisa, S. (2021). Premenopausal breast cancer risk factors and associations with molecular subtypes: A case-control study. International Journal of Breast Cancer, 2021, 5560559. https://doi.org/10.1155/2021/5560559
doi: 10.1155/2021/5560559
pubmed: 34659834
pmcid: 8519716
Chen, L.-J., Chang, Y.-J., & Chang, Y.-J. (2021). Treatment and long-term outcome of breast cancer in very young women: nationwide population-based study. BJS Open, 5(5). https://doi.org/10.1093/bjsopen/zrab087
Conte, B., Soldato, D., Razeti, M. G., Fregatti, P., de Azambuja, E., Schettini, F., … Lambertini, M. (2022). De novo metastatic breast cancer arising in young women: review of the current evidence. Clinical Breast Cancer, 22(1), 78–87 https://doi.org/10.1016/j.clbc.2021.10.001
Szollár, A., Újhelyi, M., Polgár, C., Oláh, E., Pukancsik, D., Rubovszky, G., et al. (2019). A long-term retrospective comparative study of the oncological outcomes of 598 very young (≤35 years) and young (36–45 years) breast cancer patients. European Journal of Surgical Oncology, 45(11), 2009–2015. https://doi.org/10.1016/j.ejso.2019.06.007
doi: 10.1016/j.ejso.2019.06.007
pubmed: 31189512
Suter, M. B., & Pagani, O. (2018). Should age impact breast cancer management in young women? Fine tuning of treatment guidelines. Therapeutic Advances in Medical Oncology, 10, 1758835918776923. https://doi.org/10.1177/1758835918776923
doi: 10.1177/1758835918776923
pubmed: 29977348
pmcid: 6024273
Azim, H. A. J., & Partridge, A. H. (2014). Biology of breast cancer in young women. Breast Cancer Research : BCR, 16(4), 427. https://doi.org/10.1186/s13058-014-0427-5
doi: 10.1186/s13058-014-0427-5
pubmed: 25436920
pmcid: 4303229
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010). Cancer statistics, 2010. CA, 60(5), 277–300. https://doi.org/10.3322/caac.20073
doi: 10.3322/caac.20073
pubmed: 20610543
Hassett, M. J., Hughes, M. E., Niland, J. C., Edge, S. B., Theriault, R. L., Wong, Y.-N., et al. (2008). Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer. Journal of Clinical Oncology, 26(34), 5553–5560. https://doi.org/10.1200/JCO.2008.17.9705
doi: 10.1200/JCO.2008.17.9705
pubmed: 18955448
pmcid: 2651096
Zhong, W., Tan, L., Jiang, W. G., Chen, K., You, N., Sanders, A. J., et al. (2019). Effect of younger age on survival outcomes in T1N0M0 breast cancer: A propensity score matching analysis. Journal of Surgical Oncology, 119(8), 1039–1046. https://doi.org/10.1002/jso.25457
doi: 10.1002/jso.25457
pubmed: 30892719
Copson, E., Eccles, B., Maishman, T., Gerty, S., Stanton, L., Cutress, R. I., et al. (2013). Prospective observational study of breast cancer treatment outcomes for UK women aged 18–40 years at diagnosis: The POSH study. Journal of the National Cancer Institute, 105(13), 978–988. https://doi.org/10.1093/jnci/djt134
doi: 10.1093/jnci/djt134
pubmed: 23723422
Eccles, D., Gerty, S., Simmonds, P., Hammond, V., Ennis, S., & Altman, D. G. (2007). Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): Study protocol. BMC Cancer, 7, 160. https://doi.org/10.1186/1471-2407-7-160
doi: 10.1186/1471-2407-7-160
pubmed: 17697367
pmcid: 1995215
Melina Arnold, M., Morgan, E., O’Neill, C., Bardot, A., Walsh, P., Siesling, S., et al. (2021). From early to metastatic breast cancer: A systematic review and meta-analysis of distant recurrence rates. The Breast, 9, S61. https://doi.org/10.1016/S0960-9776(21)00576-2
doi: 10.1016/S0960-9776(21)00576-2
Lima, S. M., Kehm, R. D., Swett, K., Gonsalves, L., & Terry, M. B. (2020). Trends in parity and breast cancer incidence in US women younger than 40 years from 1935 to 2015. JAMA Network Open, 3(3), e200929. https://doi.org/10.1001/jamanetworkopen.2020.0929
doi: 10.1001/jamanetworkopen.2020.0929
pubmed: 32167569
pmcid: 7070232
MacMahon, B., Cole, P., Lin, T. M., Lowe, C. R., Mirra, A. P., Ravnihar, B., et al. (1970). Age at first birth and breast cancer risk. Bulletin of the World Health Organization, 43(2), 209–221.
pubmed: 5312521
pmcid: 2427645
Rosner, B., Colditz, G. A., & Willett, W. C. (1994). Reproductive risk factors in a prospective study of breast cancer: The Nurses’ health study. American Journal of Epidemiology, 139(8), 819–835. https://doi.org/10.1093/oxfordjournals.aje.a117079
doi: 10.1093/oxfordjournals.aje.a117079
pubmed: 8178795
Russo, J., Rivera, R., & Russo, I. H. (1992). Influence of age and parity on the development of the human breast. Breast Cancer Research and Treatment, 23(3), 211–218. https://doi.org/10.1007/BF01833517
doi: 10.1007/BF01833517
pubmed: 1463860
Bonnier, P., Romain, S., Dilhuydy, J. M., Bonichon, F., Julien, J. P., Charpin, C., et al. (1997). Influence of pregnancy on the outcome of breast cancer: A case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. International Journal of Cancer, 72(5), 720–727. https://doi.org/10.1002/(sici)1097-0215(19970904)72:5<720::aid-ijc3>3.0.co;2-u
Muenst, S., Mechera, R., Däster, S., Piscuoglio, S., Ng, C. K. Y., Meier-Abt, F., et al. (2017). Pregnancy at early age is associated with a reduction of progesterone-responsive cells and epithelial Wnt signaling in human breast tissue. Oncotarget, 8(14), 22353–22360. https://doi.org/10.18632/oncotarget.16023
doi: 10.18632/oncotarget.16023
pubmed: 28423605
pmcid: 5410228
Brouckaert, O., Rudolph, A., Laenen, A., Keeman, R., Bolla, M. K., Wang, Q., et al. (2017). Reproductive profiles and risk of breast cancer subtypes: A multi-center case-only study. Breast Cancer Research, 19(1), 119. https://doi.org/10.1186/s13058-017-0909-3
doi: 10.1186/s13058-017-0909-3
pubmed: 29116004
pmcid: 5688822
Nguyen, B., Venet, D., Lambertini, M., Desmedt, C., Salgado, R., Horlings, H. M., et al. (2019). Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer. Breast Cancer Research, 21(1), 25. https://doi.org/10.1186/s13058-019-1111-6
doi: 10.1186/s13058-019-1111-6
pubmed: 30770770
pmcid: 6377756
Asztalos, S., Gann, P. H., Hayes, M. K., Nonn, L., Beam, C. A., Dai, Y., et al. (2010). Gene expression patterns in the human breast after pregnancy. Cancer Prevention Research, 3(3), 301–311. https://doi.org/10.1158/1940-6207.CAPR-09-0069
doi: 10.1158/1940-6207.CAPR-09-0069
pubmed: 20179293
Meier-Abt, F., Milani, E., Roloff, T., Brinkhaus, H., Duss, S., Meyer, D. S., et al. (2013). Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium. Breast Cancer Research, 15(2), R36. https://doi.org/10.1186/bcr3419
doi: 10.1186/bcr3419
pubmed: 23621987
pmcid: 3672662
Russo, J., Balogh, G. A., & Russo, I. H. (2008). Full-term pregnancy induces a specific genomic signature in the human breast. Cancer Epidemiology, Biomarkers & Prevention, 17(1), 51–66. https://doi.org/10.1158/1055-9965.EPI-07-0678
doi: 10.1158/1055-9965.EPI-07-0678
Mauvais-Jarvis, P., Sitruk-Ware, R., & Kuttenn, F. (1982). Luteal phase defect and breast cancer genesis. Breast Cancer Research and Treatment, 2(2), 139–150. https://doi.org/10.1007/BF01806450
doi: 10.1007/BF01806450
pubmed: 7171835
Atashgaran, V., Wrin, J., Barry, S. C., Dasari, P., & Ingman, W. V. (2016). Dissecting the biology of menstrual cycle-associated breast cancer risk. Frontier in Oncology, 6, 267. https://doi.org/10.3389/fonc.2016.00267
doi: 10.3389/fonc.2016.00267
Ziegler, R. G., Fuhrman, B. J., Moore, S. C., & Matthews, C. E. (2015). Epidemiologic studies of estrogen metabolism and breast cancer. Steroids, 99(Pt A), 67–75. https://doi.org/10.1016/j.steroids.2015.02.015
doi: 10.1016/j.steroids.2015.02.015
pubmed: 25725255
pmcid: 5722219
Apter, D., Reinilä, M., & Vihko, R. (1989). Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. Int J Can, 44(5), 783–787. https://doi.org/10.1002/ijc.2910440506
doi: 10.1002/ijc.2910440506
Russo, J., Tay, L. K., & Russo, I. H. (1982). Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Can Res and Treat, 2(1), 5–73. https://doi.org/10.1007/BF01805718
doi: 10.1007/BF01805718
Emaus, A., Espetvedt, S., Veierød, M. B., Ballard-Barbash, R., Furberg, A.-S., Ellison, P. T., et al. (2008). 17-beta-estradiol in relation to age at menarche and adult obesity in premenopausal women. Human Rep, 23(4), 919–927. https://doi.org/10.1093/humrep/dem432
doi: 10.1093/humrep/dem432
Emaus, A., Veierød, M. B., Furberg, A.-S., Espetvedt, S., Friedenreich, C., Ellison, P. T., et al. (2008). Physical activity, heart rate, metabolic profile, and estradiol in premenopausal women. Med and Sci in Sports and Exercise, 40(6), 1022–1030. https://doi.org/10.1249/MSS.0b013e318167411f
doi: 10.1249/MSS.0b013e318167411f
Jasienska, G., Ziomkiewicz, A., Lipson, S. F., Thune, I., & Ellison, P. T. (2006). High ponderal index at birth predicts high estradiol levels in adult women. American Journal of Human Biology, 18(1), 133–140. https://doi.org/10.1002/ajhb.20462
doi: 10.1002/ajhb.20462
pubmed: 16378335
Finstad, S. E., Emaus, A., Potischman, N., Barrett, E., Furberg, A.-S., Ellison, P. T., et al. (2009). Influence of birth weight and adult body composition on 17beta-estradiol levels in young women. Cancer Causes & Control, 20(2), 233–242. https://doi.org/10.1007/s10552-008-9238-2
doi: 10.1007/s10552-008-9238-2
Furberg, A.-S., Jasienska, G., Bjurstam, N., Torjesen, P. A., Emaus, A., Lipson, S. F., … Thune, I. (2005). Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiology, Biomarkers & Prevention, 14(1), 33–40.
Gómez-Flores-Ramos, L., Castro-Sánchez, A., Peña-Curiel, A., & Mohar-Betancourt, A. (2017). Molecular biology in young women with breast cancer: From tumor gene expression to DNA mutations. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 69(4), 181–192. https://doi.org/10.24875/ric.17002225
doi: 10.24875/ric.17002225
pubmed: 28776603
Copson, E. R., Maishman, T. C., Tapper, W. J., Cutress, R. I., Greville-Heygate, S., Altman, D. G., et al. (2018). Germline BRCA mutation and outcome in young-onset breast cancer (POSH): A prospective cohort study. Lancet Onc, 19(2), 169–180. https://doi.org/10.1016/S1470-2045(17)30891-4
doi: 10.1016/S1470-2045(17)30891-4
Kemp, Z., Turnbull, A., Yost, S., Seal, S., Mahamdallie, S., Poyastro-Pearson, E., et al. (2019). Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. JAMA Network Open, 2(5), e194428. https://doi.org/10.1001/jamanetworkopen.2019.4428
doi: 10.1001/jamanetworkopen.2019.4428
pubmed: 31125106
pmcid: 6632150
Terry, M. B., Michels, K. B., Brody, J. G., Byrne, C., Chen, S., Jerry, D. J., et al. (2019). Environmental exposures during windows of susceptibility for breast cancer: A framework for prevention research. Breast Can Res, 21(1), 96. https://doi.org/10.1186/s13058-019-1168-2
doi: 10.1186/s13058-019-1168-2
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295(21), 2492–2502. https://doi.org/10.1001/jama.295.21.2492
doi: 10.1001/jama.295.21.2492
pubmed: 16757721
Tao, L., Gomez, S. L., Keegan, T. H. M., Kurian, A. W., & Clarke, C. A. (2015). Breast cancer mortality in African-American and non-Hispanic White women by molecular subtype and satage at diagnosis: A population-based study. Cancer Epi Bio & Pre, 24(7), 1039–1045. https://doi.org/10.1158/1055-9965.EPI-15-0243
doi: 10.1158/1055-9965.EPI-15-0243
Lorona, N. C., Malone, K. E., & Li, C. I. (2021). Racial/ethnic disparities in risk of breast cancer mortality by molecular subtype and stage at diagnosis. Breast Can Res and Treat, 190(3), 549–558. https://doi.org/10.1007/s10549-021-06311-7
doi: 10.1007/s10549-021-06311-7
Romieu, I. I., Amadou, A., & Chajes, V. (2017). The role of diet, physical activity, body fatness, and breastfeeding in breast cancer in young women: Epidemiological evidence. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 69(4), 193–203. https://doi.org/10.24875/ric.17002263
doi: 10.24875/ric.17002263
pubmed: 28776604
Mørch, L. S., Skovlund, C. W., Hannaford, P. C., Iversen, L., Fielding, S., & Lidegaard, Ø. (2017). Contemporary hormonal contraception and the risk of breast cancer. New England J Med, 377(23), 2228–2239. https://doi.org/10.1056/NEJMoa1700732
doi: 10.1056/NEJMoa1700732
Lonard, D. M., Kumar, R., & O’Malley, B. W. (2010). Minireview: The SRC family of coactivators: An entrée to understanding a subset of polygenic diseases? Molecular Endocrinology, 24, 279–285. https://doi.org/10.1210/me.2009-0276
doi: 10.1210/me.2009-0276
pubmed: 19846539
Eswaran, J., Cyanam, D., Mudvari, P., Divijendra, S., Reddy, N., Pakala, S. B., et al. (2012). Transcriptomic landscape of breast cancers through mRNA sequencing. Science and Reports, 2, 264. https://doi.org/10.1038/srep00264
doi: 10.1038/srep00264
Shi, M., O’Brien, K. M., & Weinberg, C. R. (2020). Interactions between a polygenic risk score and non-genetic risk factors in young-onset breast cancer. Science and Reports, 10, 3242. https://doi.org/10.1038/s41598-020-60032-3
doi: 10.1038/s41598-020-60032-3
Yanes, T., Bettina Meiser, B., Kaur, R., Young, M.-A., Mitchell, P. B., Scheepers-Joynt, M., et al. (2021). Breast cancer polygenic risk scores: A 12-month prospective study of patient reported outcomes and risk management behavior. Genetics in Medicine, 23(12), 2316–2323. https://doi.org/10.1038/s41436-021-01288-6
doi: 10.1038/s41436-021-01288-6
pubmed: 34341522
Mars, N., Widén, E., Kerminen, S., Meretoja, T., Pirinen, M., Parolo, D. B., P., et al. (2020). The role of polygenic risk and susceptibility genes in breast cancer over the course of life. Nature Communications, 11(1), 6383. https://doi.org/10.1038/s41467-020-19966-5
doi: 10.1038/s41467-020-19966-5
pubmed: 33318493
pmcid: 7736877
Torkamani, A., Wineinger, N. E., & Topol, E. J. (2018). The personal and clinical utility of polygenic risk scores. Nature Reviews Genetics, 19, 581–590. https://doi.org/10.1038/s41576-018-0018-x
doi: 10.1038/s41576-018-0018-x
pubmed: 29789686
Olsen, M., Fischer, K., Bossuyt, P. M., & Goetghebeur, E. (2021). Evaluating the prognostic performance of a polygenic risk score for breast cancer risk stratification. BMC Cancer, 21(1), 1351. https://doi.org/10.1186/s12885-021-08937-8
doi: 10.1186/s12885-021-08937-8
pubmed: 34930164
pmcid: 8691010
Sandiford, O. A., Donnelly, R. J., El-Far, M. H., Burgmeyer, L. M., Sinha, G., Pamarthi, S. H., et al. (2021). Mesenchymal stem cell-secreted extracellular vesicles instruct stepwise dedifferentiation of breast cancer cells into dormancy at the bone marrow perivascular region. Cancer Research, 81(6), 1567–1582. https://doi.org/10.1158/0008-5472.CAN-20-2434
doi: 10.1158/0008-5472.CAN-20-2434
pubmed: 33500249
Bliss, S. A., Sinha, G., Sandiford, O. A., Williams, L. M., Engelberth, D. J., Guiro, K., et al. (2016). Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Research, 76(19), 5832–5844. https://doi.org/10.1158/0008-5472.CAN-16-1092
doi: 10.1158/0008-5472.CAN-16-1092
pubmed: 27569215
Moore, C. A., Ferrer, A. I., Alonso, S., Pamarthi, S. H., Sandiford, O. A., & Rameshwar, P. (2021). Exosomes in the healthy and malignant bone marrow microenvironment. Advances in Experimental Medicine and Biology, 1350, 67–89. https://doi.org/10.1007/978-3-030-83282-7_3
doi: 10.1007/978-3-030-83282-7_3
pubmed: 34888844
Hartkopf, A. D., Brucker, S. Y., Taran, F. A., Harbeck, N., von Au, A., Naume, B., et al. (2021). Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. European Journal of Cancer, 154, 128–137. https://doi.org/10.1016/j.ejca.2021.06.028
doi: 10.1016/j.ejca.2021.06.028
pubmed: 34265505
Nassar, F. J., Chamandi, G., Tfaily, M. A., Zgheib, N. K., & Nasr, R. (2020). Peripheral blood-based biopsy for breast cancer risk prediction and early detection. Front Med (Lausanne), 7(28), 2020. https://doi.org/10.3389/fmed.2020.00028.eCollection
doi: 10.3389/fmed.2020.00028.eCollection
Jordan, K. R., Hall, J. K., Schedin, T., Borakove, M., Xian, J. J., Dzieciatkowska, M., et al. (2020). Extracellular vesicles from young women’s breast cancer patients drive increased invasion of non-malignant cells via the focal adhesion kinase pathway: A proteomic approach. Breast Cancer Research, 22(1), 128. https://doi.org/10.1186/s13058-020-01363-x
doi: 10.1186/s13058-020-01363-x
pubmed: 33225939
pmcid: 7681773
Bushnell, G. G., Deshmukh, A. P., den Hollander, P., Luo, M., Soundararajan, R., Jia, D., et al. (2021). Breast cancer dormancy: Need for clinically relevant models to address current gaps in knowledge. NPJ Breast Cancer, 7(1), 66. https://doi.org/10.1038/s41523-021-00269-x
doi: 10.1038/s41523-021-00269-x
pubmed: 34050189
pmcid: 8163741
Patel, S. A., Ramkissoon, S. H., Bryan, M., Pliner, L. F., Dontu, G., Patel, P. S., et al. (2012). Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Science and Reports, 2, 906. https://doi.org/10.1038/srep00906
doi: 10.1038/srep00906
Greco, S. J., Ayer, S., Guiro, K., Sinha, G., Donnelly, R. J., El-Far, M. H., et al. (2021). Restoration of aged hematopoietic cells by their young counterparts through instructive microvesicles release. Aging (Albany NY), 13(21), 23981–24016. https://doi.org/10.18632/aging.203689
doi: 10.18632/aging.203689
Kashiwagi, S., Yashiro, M., Takashima, T., Aomatsu, N., Kawajiri, H., Ogawa, Y., et al. (2013). c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer. The British Journal of Surgery, 100(4), 490–496. https://doi.org/10.1002/bjs.9021
doi: 10.1002/bjs.9021
pubmed: 23319435
Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., et al. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine, 15(8), 907–913. https://doi.org/10.1038/nm.2000
doi: 10.1038/nm.2000
pubmed: 19648928
Smart, C. E., Wronski, A., French, J. D., Edwards, S. L., Asselin-Labat, M.-L., Waddell, N., et al. (2011). Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit. Oncogene, 30(13), 1597–1607. https://doi.org/10.1038/onc.2010.538
doi: 10.1038/onc.2010.538
pubmed: 21132007
McCredie, M. R. E., Dite, G. S., Southey, M. C., Venter, D. J., Giles, G. G., & Hopper, J. L. (2003). Risk factors for breast cancer in young women by oestrogen receptor and progesterone receptor status. British Journal of Cancer, 89(9), 1661–1663. https://doi.org/10.1038/sj.bjc.6601293
doi: 10.1038/sj.bjc.6601293
pubmed: 14583766
pmcid: 2394423
Joshi, P. A., Jackson, H. W., Beristain, A. G., Di Grappa, M. A., Mote, P. A., Clarke, C. L., et al. (2010). Progesterone induces adult mammary stem cell expansion. Nature, 465(7299), 803–807. https://doi.org/10.1038/nature09091
doi: 10.1038/nature09091
pubmed: 20445538
Gonzalez-Suarez, E., Jacob, A. P., Jones, J., Miller, R., Roudier-Meyer, M. P., Erwert, R., et al. (2010). RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature, 468(7320), 103–107. https://doi.org/10.1038/nature09495
doi: 10.1038/nature09495
pubmed: 20881963
Schramek, D., Leibbrandt, A., Sigl, V., Kenner, L., Pospisilik, J. A., Lee, H. J., … Penninger, J. M. (2010). Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature, 468(7320), 98–102 https://doi.org/10.1038/nature09387
Azim, H. A., Jr., Michiels, S., Bedard, P. L., Singhal, S. K., Criscitiello, C., Ignatiadis, M., et al. (2012). Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clinical Cancer Research, 18(5), 1341–1351. https://doi.org/10.1158/1078-0432.CCR-11-2599
doi: 10.1158/1078-0432.CCR-11-2599
pubmed: 22261811
Haynes, B. P., Viale, G., Galimberti, V., Rotmensz, N., Gibelli, B., Smith, I. E., & Dowsett, M. (2014). Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer. Breast cancer Research and Treatment, 148(2), 327–335. https://doi.org/10.1007/s10549-014-3181-6
doi: 10.1007/s10549-014-3181-6
pubmed: 25367875
Azim, H. A., Jr., Peccatori, F. A., Brohée, S., Branstetter, D., Loi, S., Viale, G., et al. (2015). RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Research, 17, 24. https://doi.org/10.1186/s13058-015-0538-7
doi: 10.1186/s13058-015-0538-7
pubmed: 25849336
pmcid: 4374174
Van Poznak, C., Cross, S. S., Saggese, M., Hudis, C., Panageas, K. S., Norton, L., et al. (2006). Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. Journal of Clinical Pathology, 59(1), 56–63. https://doi.org/10.1136/jcp.2005.026534
doi: 10.1136/jcp.2005.026534
pubmed: 16394281
pmcid: 1860269
Sarink, D., Schock, H., Johnson, T., Overvad, K., Holm, H., Tjønneland, A., et al. (2017). Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: results from the EPIC cohort. Cancer Prevention Research (Philadelphia, Pa.), 10(9), 525–534. https://doi.org/10.1158/1940-6207.CAPR-17-0125
doi: 10.1158/1940-6207.CAPR-17-0125
Gabrielson, M., Azam, S., Hardell, E., Holm, M., Ubhayasekera, K. A., Eriksson, M., … Hall, P. (2020). Hormonal determinants of mammographic density and density change. Breast Cancer Research, 22(1), 95 https://doi.org/10.1186/s13058-020-01332-4
Toriola, A. T., Appleton, C. M., Zong, X., Luo, J., Weilbaecher, K., Tamimi, R. M., & Colditz, G. A. (2018). Circulating receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL), and mammographic density in premenopausal women. Cancer Prevention Research (Philadelphia, Pa.), 11(12), 789–796. https://doi.org/10.1158/1940-6207.CAPR-18-0199
doi: 10.1158/1940-6207.CAPR-18-0199
Toriola, A. T., Dang, H. X., Hagemann, I. S., Appleton, C. M., Colditz, G. A., Luo, J., & Maher, C. A. (2017). Increased breast tissue receptor activator of nuclear factor-κB ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women. Oncotarget, 8(43), 73787–73792. https://doi.org/10.18632/oncotarget.17909
doi: 10.18632/oncotarget.17909
pubmed: 29088745
pmcid: 5650300
Olsson, H. L., & Olsson, M. L. (2020). The menstrual cycle and risk of breast cancer: A review. Frontiers in Oncology, 10, 21. https://doi.org/10.3389/fonc.2020.00021
doi: 10.3389/fonc.2020.00021
pubmed: 32038990
pmcid: 6993118
Duncan, W. C. (2021). The inadequate corpus luteum. Reproduction & fertility, 2(1), C1–C7. https://doi.org/10.1530/RAF-20-0044
doi: 10.1530/RAF-20-0044
Brisken, C., Hess, K., & Jeitziner, R. (2015). Progesterone and overlooked endocrine pathways in breast cancer pathogenesis. Endocrinology, 156(10), 3442–3450. https://doi.org/10.1210/en.2015-1392
doi: 10.1210/en.2015-1392
pubmed: 26241069
pmcid: 4588833
Wilson, C., Brown, H., & Holen, I. (2016). The endocrine influence on the bone microenvironment in early breast cancer. Endocrine Related Cancer, 23(12), R567–R576. https://doi.org/10.1530/ERC-16-0238
doi: 10.1530/ERC-16-0238
pubmed: 27687494
Pardo, I., Lillemoe, H. A., Blosser, R. J., Choi, M., Sauder, C. A. M., Doxey, D. K., & a;. (2014). Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank. Breast Cancer Research, 16(2), R26. https://doi.org/10.1186/bcr3627
doi: 10.1186/bcr3627
pubmed: 24636070
pmcid: 4053088
Savolainen-Peltonen, H., Vihma, V., Wang, F., Turpeinen, U., Hämäläinen, E., Haanpää, M., et al. (2018). Estrogen biosynthesis in breast adipose tissue during menstrual cycle in women with and without breast cancer. Gynecological Endocrinology, 34(12), 1039–1043. https://doi.org/10.1080/09513590.2018.1474868
doi: 10.1080/09513590.2018.1474868
pubmed: 29790386
Hetemäki, N., Mikkola, T. S., Tikkanen, M. J., Wang, F., Hämäläinen, E., Turpeinen, U., et al. (2021). Adipose tissue estrogen production and metabolism in premenopausal women. J of Steroid Bio and Mol Bio, 209, 105849. https://doi.org/10.1016/j.jsbmb.2021.105849
doi: 10.1016/j.jsbmb.2021.105849
Zhang, Y., Nadeau, M., Faucher, F., Lescelleur, O., Biron, S., Daris, M., et al. (2009). Progesterone metabolism in adipose cells. Mol and Cell End, 298(1–2), 76–83. https://doi.org/10.1016/j.mce.2008.09.034
doi: 10.1016/j.mce.2008.09.034
Kershaw, E. E., & Flier, J. S. (2004). Adipose tissue as an endocrine organ. J Cli Endo and Met, 89(6), 2548–2556. https://doi.org/10.1210/jc.2004-0395
doi: 10.1210/jc.2004-0395
Wiebe, J. P., Muzia, D., Hu, J., Szwajcer, D., Hill, S. A., & Seachrist, J. L. (2000). The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Research, 60(4), 936–943.
pubmed: 10706108
Lee, W., Wang, Z., Saffern, M., Jun, T., & Huang, K.-L. (2021). Genomic and molecular features distinguish young adult cancer from later-onset cancer. Cell Reports, 37(7), 110005. https://doi.org/10.1016/j.celrep.2021.110005
doi: 10.1016/j.celrep.2021.110005
pubmed: 34788626
Callihan, E. B., Gao, D., Jindal, S., Lyons, T. R., Manthey, E., Edgerton, S., et al. (2013). Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Can Res & Treat, 138(2), 549–559. https://doi.org/10.1007/s10549-013-2437-x
doi: 10.1007/s10549-013-2437-x
Goddard, E. T., Bassale, S., Schedin, T., Jindal, S., Johnston, J., Cabral, E., et al. (2019). Association between postpartum breast cancer diagnosis and metastasis and the clinical features underlying risk. JAMA Network Open, 2(1), e186997. https://doi.org/10.1001/jamanetworkopen.2018.6997
doi: 10.1001/jamanetworkopen.2018.6997
pubmed: 30646210
pmcid: 6484560
Amant, F., von Minckwitz, G., Han, S. N., Bontenbal, M., Ring, A. E., Giermek, J., et al. (2013). Prognosis of women with primary breast cancer diagnosed during pregnancy: Results from an international collaborative study. J Cli Onc, 31(20), 2532–2539. https://doi.org/10.1200/JCO.2012.45.6335
doi: 10.1200/JCO.2012.45.6335
Johansson, A. L. V., Andersson, T.M.-L., Hsieh, C.-C., Cnattingius, S., & Lambe, M. (2011). Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum. Cancer Epidemiology, Biomarkers & Prevention, 20(9), 1865–1872. https://doi.org/10.1158/1055-9965.EPI-11-0515
doi: 10.1158/1055-9965.EPI-11-0515
Hartman, E. K., & Eslick, G. D. (2016). The prognosis of women diagnosed with breast cancer before, during and after pregnancy: A meta-analysis. Breast Can Res and Treat, 160(2), 347–360. https://doi.org/10.1007/s10549-016-3989-3
doi: 10.1007/s10549-016-3989-3
Lyons, T. R., O’Brien, J., Borges, V. F., Conklin, M. W., Keely, P. J., Eliceiri, K. W., … Schedin, P. (2011). Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nature Med, 17(9), 1109–1115 https://doi.org/10.1038/nm.2416
McDaniel, S. M., Rumer, K. K., Biroc, S. L., Metz, R. P., Singh, M., Porter, W., & Schedin, P. (2006). Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Path, 168(2), 608–620. https://doi.org/10.2353/ajpath.2006.050677
doi: 10.2353/ajpath.2006.050677
pubmed: 16436674
pmcid: 1606507
Martinson, H. A., Jindal, S., Durand-Rougely, C., Borges, V. F., & Schedin, P. (2015). Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression. Int J Can, 136(8), 1803–1813. https://doi.org/10.1002/ijc.29181
doi: 10.1002/ijc.29181
Watson, C. J., & Kreuzaler, P. A. (2011). Remodeling mechanisms of the mammary gland during involution. Int J Dev Bio, 55(7–9), 757–762. https://doi.org/10.1387/ijdb.113414cw
doi: 10.1387/ijdb.113414cw
Lindahl, G., Rzepecka, A., & Dabrosin, C. (2019). Increased extracellular osteopontin levels in normal human breast tissue at high risk of developing cancer and its association with inflammatory biomarkers in situ. Frontiers in Oncology, 9, 746. https://doi.org/10.3389/fonc.2019.00746
doi: 10.3389/fonc.2019.00746
pubmed: 31475105
pmcid: 6707004
Ferguson, J. E., Schor, A. M., Howell, A., & Ferguson, M. W. (1992). Changes in the extracellular matrix of the normal human breast during the menstrual cycle. Cell and Tissue Res, 268(1), 167–177. https://doi.org/10.1007/BF00338066
doi: 10.1007/BF00338066
Lu, P., Weaver, V. M., & Werb, Z. (2012). The extracellular matrix: A dynamic niche in cancer progression. Journal of Cell Bio, 196(4), 395–406. https://doi.org/10.1083/jcb.201102147
doi: 10.1083/jcb.201102147
Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420(6917), 860–867. https://doi.org/10.1038/nature01322
doi: 10.1038/nature01322
pubmed: 12490959
pmcid: 2803035
Guo, Q., Minnier, J., Burchard, J., Chiotti, K., Spellman, P., & Schedin, P. (2017). Physiologically activated mammary fibroblasts promote postpartum mammary cancer. JCI Insight, 2(6), e89206. https://doi.org/10.1172/jci.insight.89206
doi: 10.1172/jci.insight.89206
pubmed: 28352652
pmcid: 5358521
Körner, A., Bernard, A., Fitzgerald, J. C., Alarcon-Barrera, J. C., Kostidis, S., Kaussen, T., … Mirakaj, V. (2021). Sema7A is crucial for resolution of severe inflammation. Proceedings of the National Academy of Sciences of the United States of America, 118(9). https://doi.org/10.1073/pnas.2017527118
Tarullo, S. E., Hill, R. C., Hansen, K. C., Behbod, F., Borges, V. F., Nelson, A. C., & Lyons, T. R. (2020). Postpartum breast cancer progression is driven by semaphorin 7a-mediated invasion and survival. Oncogene, 39(13), 2772–2785. https://doi.org/10.1038/s41388-020-1192-9
doi: 10.1038/s41388-020-1192-9
pubmed: 32020054
pmcid: 7103487
Borges, V. F., Hu, J., Young, C., Maggard, J., Parris, H. J., Gao, D., & Lyons, T. R. (2020). Semaphorin 7a is a biomarker for recurrence in postpartum breast cancer. NPJ Breast Can. https://doi.org/10.1038/s41523-020-00198-1
doi: 10.1038/s41523-020-00198-1
Crump, L. S., Wyatt, G. L., Rutherford, T. R., Richer, J. K., Porter, W. W., & Lyons, T. R. (2021). Hormonal regulation of semaphorin 7a in ER(+) breast cancer drives therapeutic resistance. Cancer Research, 81(1), 187–198. https://doi.org/10.1158/0008-5472.CAN-20-1601
doi: 10.1158/0008-5472.CAN-20-1601
pubmed: 33122307
Park, C., Yoon, K.-A., Kim, J., Park, I. H., Park, S. J., Kim, M. K., et al. (2019). Integrative molecular profiling identifies a novel cluster of estrogen receptor-positive breast cancer in very young women. Cancer Science, 110(5), 1760–1770. https://doi.org/10.1111/cas.13982
doi: 10.1111/cas.13982
pubmed: 30811755
pmcid: 6500962
Yau, C., Fedele, V., Roydasgupta, R., Fridlyand, J., Hubbard, A., Gray, J. W., et al. (2007). Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Research, 9(5), R59. https://doi.org/10.1186/bcr1765
doi: 10.1186/bcr1765
pubmed: 17850661
pmcid: 2216076
Anders, C. K., Hsu, D. S., Broadwater, G., Acharya, C. R., Foekens, J. A., Zhang, Y., et al. (2008). Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. Journal of Clinical Oncology, 26(20), 3324–3330. https://doi.org/10.1200/JCO.2007.14.2471
doi: 10.1200/JCO.2007.14.2471
pubmed: 18612148
Azim, H. A., Jr., Nguyen, B., Brohée, S., Zoppoli, G., & Sotiriou, C. (2015). Genomic aberrations in young and elderly breast cancer patients. BMC Medicine, 13, 266. https://doi.org/10.1186/s12916-015-0504-3
doi: 10.1186/s12916-015-0504-3
pubmed: 26467651
pmcid: 4606505
Waks, A. G., Kim, D., Jain, E., Snow, C., Kirkner, G. J., Rosenberg, S. M., et al. (2022). Somatic and germline genomic alterations in very young women with breast cancer. Clinical Can Res. https://doi.org/10.1158/1078-0432.CCR-21-2572
doi: 10.1158/1078-0432.CCR-21-2572
Gu, X., Wang, B., Zhu, H., Zhou, Y., Horning, A. M., Huang, T.H.-M., et al. (2020). Age-associated genes in human mammary gland drive human breast cancer progression. Breast Can Res, 22(1), 64. https://doi.org/10.1186/s13058-020-01299-2
doi: 10.1186/s13058-020-01299-2
Colak, D., Nofal, A., Albakheet, A., Nirmal, M., Jeprel, H., Eldali, A., et al. (2013). Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS ONE, 8(5), e63204. https://doi.org/10.1371/journal.pone.0063204
doi: 10.1371/journal.pone.0063204
pubmed: 23704896
pmcid: 3660335
Kan, Z., Ding, Y., Kim, J., Jung, H. H., Chung, W., Lal, S., et al. (2018). Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nature Communications, 9(1), 1725. https://doi.org/10.1038/s41467-018-04129-4
doi: 10.1038/s41467-018-04129-4
pubmed: 29713003
pmcid: 5928087
Jindal, S., Pennock, N. D., Sun, D., Horton, W., Ozaki, M. K., Narasimhan, J., et al. (2021). Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes. Nature Communications, 12(1), 6341. https://doi.org/10.1038/s41467-021-26505-3
doi: 10.1038/s41467-021-26505-3
pubmed: 34732713
pmcid: 8566602
Pirone, J. R., D’Arcy, M., Stewart, D. A., Hines, W. C., Johnson, M., Gould, M. N., et al. (2012). Age-associated gene expression in normal breast tissue mirrors qualitative age-at-incidence patterns for breast cancer. Cancer Epidemiology, Biomarkers & Prevention, 21(10), 1735–1744. https://doi.org/10.1158/1055-9965.EPI-12-0451
doi: 10.1158/1055-9965.EPI-12-0451
Wang, J., Peng, C., Guranich, C., Heng, Y. J., Baker, G. M., Rubadue, C. A., et al. (2021). Early-life body adiposity and the breast tumor transcriptome. Journal of the National Cancer Institute, 113(6), 778–784. https://doi.org/10.1093/jnci/djaa169
doi: 10.1093/jnci/djaa169
pubmed: 33136151
Kang, T., Yau, C., Wong, C. K., Sanborn, J. Z., Newton, Y., Vaske, C., et al. (2020). A risk-associated active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population. Breast Cancer Research : BCR, 22(1), 81. https://doi.org/10.1186/s13058-020-01322-6
doi: 10.1186/s13058-020-01322-6
pubmed: 32736587
pmcid: 7395362
Osako, T., Lee, H., Turashvili, G., Chiu, D., McKinney, S., Joosten, S. E. P., et al. (2020). Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects. Nature Cancer, 1(5), 518–532. https://doi.org/10.1038/s43018-020-0060-4
doi: 10.1038/s43018-020-0060-4
pubmed: 35121983
Deng, G., Lu, Y., Zlotnikov, G., Thor, A. D., & Smith, H. S. (1996). Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science (New York, N.Y.), 274(5295), 2057–2059. https://doi.org/10.1126/science.274.5295.2057
doi: 10.1126/science.274.5295.2057
Evans, A., Trimboli, R. M., Athanasiou, A., Balleyguier, C., Baltzer, P. A., Bick, U., et al. (2018). Breast ultrasound: Recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights into Imaging, 9(4), 449–461. https://doi.org/10.1007/s13244-018-0636-z
doi: 10.1007/s13244-018-0636-z
pubmed: 30094592
pmcid: 6108964
Denduluri, N., Somerfield, M. R., Chavez-MacGregor, M., Comander, A. H., Dayao, Z., Eisen, A., … Giordano, S. H. (2021). Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO guideline update. Journal of Clinical Oncology, 39(6), 685–693 https://doi.org/10.1200/JCO.20.02510
Chaudhary, L. N. (2021). Clinical and psychosocial challenges of breast cancer in adolescent and young adult women under the age of 40 years. JCO Oncology Practice, 17(6), 317–319. https://doi.org/10.1200/OP.21.00111
doi: 10.1200/OP.21.00111
pubmed: 33793341
pmcid: 8258001
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., et al. (2018). Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. New England Journal of Medicine, 379(2), 111–121. https://doi.org/10.1056/NEJMoa1804710
doi: 10.1056/NEJMoa1804710
pubmed: 29860917
Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D. F., Pritchard, K. I., Albain, K. S., et al. (2019). Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. New England journal of medicine, 380(25), 2395–2405. https://doi.org/10.1056/NEJMoa1904819
doi: 10.1056/NEJMoa1904819
pubmed: 31157962
Piccart, M., van ’t Veer, L. J., Poncet, C., Lopes Cardozo, J. M. N., Delaloge, S., Pierga, J. Y., et al. (2021). 70-gene signature as an aid for treatment decisions in early breast cancer: Updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncology, 22(4), 476–488. https://doi.org/10.1016/S1470-2045(21)00007-3
doi: 10.1016/S1470-2045(21)00007-3
pubmed: 33721561
Kalinsky, K., Barlow, W. E., Gralow, J. R., Meric-Bernstam, F., Albain, K. S., Hayes, D. F., et al. (2021). 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. New England Journal of Medicine, 385(25), 2336–2347. https://doi.org/10.1056/NEJMoa2108873
doi: 10.1056/NEJMoa2108873
pubmed: 34914339
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., et al. (2020). Pembrolizumab for early triple-negative breast cancer. New England Journal of Medicine, 382(9), 810–821. https://doi.org/10.1056/NEJMoa1910549
doi: 10.1056/NEJMoa1910549
pubmed: 32101663
Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A., et al. (2017). Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: Secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncology, 3(10), 1378–1385. https://doi.org/10.1001/jamaoncol.2017.1007
doi: 10.1001/jamaoncol.2017.1007
pubmed: 28715532
pmcid: 5710508
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., et al. (2015). Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603. Journal of Clinical Oncology, 33(1), 13–21. https://doi.org/10.1200/JCO.2014.57.0572
doi: 10.1200/JCO.2014.57.0572
pubmed: 25092775
Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chem... | OncologyPRO. (n.d.). Retrieved February 11, 2022, from https://oncologypro.esmo.org/meeting-resources/esmo-congress/event-free-survival-efs-overall-survival-os-and-safety-of-adding-veliparib-v-plus-carboplatin-cb-or-carboplatin-alone-to-neoadjuvant-chem
Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., et al. (2021). Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up. Journal of Clinical Oncology, 39(13), 1448–1457. https://doi.org/10.1200/JCO.20.01204
doi: 10.1200/JCO.20.01204
pubmed: 33539215
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., et al. (2019). Trastuzumab emtansine for residual invasive HER2-positive breast cancer. New England Journal of Medicine, 380(7), 617–628. https://doi.org/10.1056/NEJMoa1814017
doi: 10.1056/NEJMoa1814017
Gulia, S., Kannan, S., Badwe, R., & Gupta, S. (2020). Evaluation of 1-year vs shorter durations of adjuvant trastuzumab among patients with early breast cancer: An individual participant data and trial-level meta-analysis. JAMA Network Open, 3(8), e2011777. https://doi.org/10.1001/jamanetworkopen.2020.11777
doi: 10.1001/jamanetworkopen.2020.11777
pubmed: 32833018
pmcid: 7445596
Cathcart-Rake, E. J., Ruddy, K. J., Bleyer, A., & Johnson, R. H. (2021). Breast cancer in adolescent and young adult women under the age of 40 years. JCO Oncology Practice, 17(6), 305–313. https://doi.org/10.1200/OP.20.00793
doi: 10.1200/OP.20.00793
pubmed: 33449828
Lu, Y.-S., Wong, A., Kim, H.-J. (2021). Ovarian function suppression with luteinizing hormone-releasing hormone agonists for the treatment of hormone receptor-positive early breast cancer in premenopausal women. Front. Oncol., Article 700722. https://doi.org/10.3389/fonc.2021.700722
Partridge, A. H. (2013). Cancer survivorship and the young breast cancer patient: Addressing the important issues. The Oncologist, 18(8), e19-20. https://doi.org/10.1634/theoncologist.2013-0300
doi: 10.1634/theoncologist.2013-0300
pubmed: 23986342
pmcid: 3755937
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., … Lindor, N. M. (2015). American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 33(31), 3660–3667 https://doi.org/10.1200/JCO.2015.63.0996
Moore, H. C. F., Unger, J. M., Phillips, K.-A., Boyle, F., Hitre, E., Moseley, A., et al. (2019). Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230. Journal of the National Cancer Institute, 111(2), 210–213. https://doi.org/10.1093/jnci/djy185
doi: 10.1093/jnci/djy185
pubmed: 30371800
Lambertini, M., Boni, L., Michelotti, A., Gamucci, T., Scotto, T., Gori, S., et al. (2015). Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: A randomized clinical trial. JAMA, 314(24), 2632–2640. https://doi.org/10.1001/jama.2015.17291
doi: 10.1001/jama.2015.17291
pubmed: 26720025
Leonard, R. C. F., Adamson, D. J. A., Bertelli, G., Mansi, J., Yellowlees, A., Dunlop, J., et al. (2017). GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: The Anglo Celtic Group OPTION trial. Annals of Oncology, 28(8), 1811–1816. https://doi.org/10.1093/annonc/mdx184
doi: 10.1093/annonc/mdx184
pubmed: 28472240
Lambertini, M., Blondeaux, E., Bruzzone, M., Perachino, M., Anderson, R. A., de Azambuja, E., et al. (2021). Pregnancy sfter breast cancer: A systematic review and meta-Analysis. Journal of Clinical Oncology, 39(29), 3293–3305. https://doi.org/10.1200/JCO.21.00535
doi: 10.1200/JCO.21.00535
pubmed: 34197218
Lambertini, M., Ameye, L., Hamy, A.-S., Zingarello, A., Poorvu, P. D., Carrasco, E., et al. (2020). Pregnancy after breast cancer in patients with germline BRCA mutations. Journal of Clinical Oncology, 38(26), 3012–3023. https://doi.org/10.1200/JCO.19.02399
doi: 10.1200/JCO.19.02399
pubmed: 32673153
Regan, M. M., Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Viale, G., et al. (2016). Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. Journal of Clinical Oncology, 2016(34), 2221–2231. https://doi.org/10.1200/JCO.2015.64.3171
doi: 10.1200/JCO.2015.64.3171
Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., et al. (2018). Tailoring adjuvant endocrine therapy for premenopausal breast cancer. New England Journal of Medicine, 379(2), 122–137. https://doi.org/10.1056/NEJMoa1803164
doi: 10.1056/NEJMoa1803164
pubmed: 29863451
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). (2022). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: A patient-level meta-analysis of 7030 women from four randomised trials. The lancet Oncology. https://doi.org/10.1016/S1470-2045(21)00758-0
doi: 10.1016/S1470-2045(21)00758-0
Coleman, R., Finkelstein, D. M., Barrios, C., Martin, M., Iwata, H., et al. (2020). Adjuvant denosumab in early breast cancer (D-CARE): An international, multicentre, randomised, controlled, phase 3 trial. The lancet Oncology, 21, 60–72. https://doi.org/10.1016/S1470-2045(19)30687-4
doi: 10.1016/S1470-2045(19)30687-4
pubmed: 31806543
Francesco Perrone, F., Laurentiis, M. D., De Placido, S., Orditura, M., Cinieri, S., Riccardi, F., et al. (2019). Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer. The HOBOE phase 3 randomised trial. European Journal of Cancer, 118, 178–186. https://doi.org/10.1016/j.ejca.2019.05.004
doi: 10.1016/j.ejca.2019.05.004
pubmed: 31164265
Arlindo, R., Ferreira, J. R., Miranda, A., Mayer, A., Passos-Coelho, J. L., Brito, M., et al. (2019). Effectiveness of adjuvant ovarian function suppression in premenopausal women with early breast cancer: A multicenter cohort study. Clinical Breast Cancer, 19(5), 654–667. https://doi.org/10.1016/j.clbc.2019.06.003
doi: 10.1016/j.clbc.2019.06.003
Early Breast Cancer Trialists’ Collaborative G. (2015). Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. Lancet, 386, 1353–1361. https://doi.org/10.1016/S0140-6736(15)60908-4
doi: 10.1016/S0140-6736(15)60908-4
Coleman, R., Hall, A., Albanell, J., Hanby, A., Bell, R., Cameron, D., et al. (2017). Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: A secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. The lancet Oncology, 18, 1543–1552. https://doi.org/10.1016/S1470-2045(17)30603-4
doi: 10.1016/S1470-2045(17)30603-4
pubmed: 29037984
Vila, J., Gandini, S., & Gentilini, O. (2015). Overall survival according to type of surgery in young (≤40 years) early breast cancer patients: A systematic meta-analysis comparing breast-conserving surgery versus mastectomy. Breast (Edinburgh, Scotland), 24(3), 175–181. https://doi.org/10.1016/j.breast.2015.02.002
doi: 10.1016/j.breast.2015.02.002
Tolaney, S. M., Guo, H., Pernas, S., Barry, W. T., Dillon, D. A., Ritterhouse, L., et al. (2019). Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology, 37(22), 1868–1875. https://doi.org/10.1200/JCO.19.00066
doi: 10.1200/JCO.19.00066
pubmed: 30939096
pmcid: 7587424
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., et al. (2019). Overall survival with ribociclib plus endocrine therapy in breast cancer. New England Journal of Medicine, 381(4), 307–316. https://doi.org/10.1056/NEJMoa1903765
doi: 10.1056/NEJMoa1903765
pubmed: 31166679